The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A - PubMed (original) (raw)
Affiliations
- PMID: 7831671
The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A
P Savi et al. Thromb Haemost. 1994 Aug.
Abstract
Clopidogrel and ticlopidine are two well known selective anti-ADP agents which are inactive in vitro and must be administered in vivo to fully exhibit their antiaggregating and antithrombotic effects. Since previous studies have clearly demonstrated that the activation steps take place in the liver, we examined the effect of specific induction or inhibition of cytochrome P450 subfamilies on the antiaggregating activity of clopidogrel. SKF 525-A, a global cytochrome P450 inhibitor, dramatically decreased the antiaggregating effect of clopidogrel, therefore indicating that cytochrome P450 enzymes are involved in the hepatic activation of clopidogrel. The efficacy of clopidogrel was increased in animals pretreated with 3-methylcholanthrene and beta-naphthoflavone, indicating that the cytochrome P450-1A subfamily pathway was mainly involved in the activating metabolism of clopidogrel. The use of specific antibodies directed against the various cytochrome P450 subfamilies ascertained this observation.
Similar articles
- Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Mitsios JV, et al. Circulation. 2004 Mar 23;109(11):1335-8. doi: 10.1161/01.CIR.0000124581.18191.15. Epub 2004 Mar 15. Circulation. 2004. PMID: 15023882 Clinical Trial. - P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM, Savi P. Herbert JM, et al. Semin Vasc Med. 2003 May;3(2):113-22. doi: 10.1055/s-2003-40669. Semin Vasc Med. 2003. PMID: 15199474 Review. - Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation-induced toxicity in rat small intestine.
Wang J, Albertson CM, Zheng H, Fink LM, Herbert JM, Hauer-Jensen M. Wang J, et al. Thromb Haemost. 2002 Jan;87(1):122-8. Thromb Haemost. 2002. PMID: 11848440 - Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.
Ma TK, Lam YY, Tan VP, Kiernan TJ, Yan BP. Ma TK, et al. Pharmacol Ther. 2010 Feb;125(2):249-59. doi: 10.1016/j.pharmthera.2009.10.008. Epub 2009 Nov 14. Pharmacol Ther. 2010. PMID: 19919843 Review.
Cited by
- Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects.
Teng R, Mitchell P, Butler K. Teng R, et al. Eur J Clin Pharmacol. 2013 Apr;69(4):877-83. doi: 10.1007/s00228-012-1436-x. Epub 2012 Oct 24. Eur J Clin Pharmacol. 2013. PMID: 23093043 Clinical Trial. - Antiplatelet agents and proton pump inhibitors - personalizing treatment.
Lin E, Padmanabhan R, Moonis M. Lin E, et al. Pharmgenomics Pers Med. 2010;3:101-9. doi: 10.2147/pgpm.s7298. Epub 2010 Jun 28. Pharmgenomics Pers Med. 2010. PMID: 23226046 Free PMC article. - Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL. Varenhorst C, et al. Eur Heart J. 2009 Jul;30(14):1744-52. doi: 10.1093/eurheartj/ehp157. Epub 2009 May 9. Eur Heart J. 2009. PMID: 19429918 Free PMC article. Clinical Trial. - Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy.
Jarrar M, Behl S, Manyam G, Ganah H, Nazir M, Nasab R, Moustafa K. Jarrar M, et al. Mol Biol Rep. 2016 Jun;43(6):473-84. doi: 10.1007/s11033-016-3983-1. Epub 2016 Apr 12. Mol Biol Rep. 2016. PMID: 27072373 Review. - The role of platelets in leukocyte recruitment in chronic contact hypersensitivity induced by repeated elicitation.
Tamagawa-Mineoka R, Katoh N, Ueda E, Takenaka H, Kita M, Kishimoto S. Tamagawa-Mineoka R, et al. Am J Pathol. 2007 Jun;170(6):2019-29. doi: 10.2353/ajpath.2007.060881. Am J Pathol. 2007. PMID: 17525269 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical